Published in Cancer Weekly, December 10th, 2002
The trial is expected to begin in 2003 and to enroll approximately 1,000 patients over 12 months.
"The mission of the GOG is to improve the lives and outcomes of patients with gynecologic cancers. While we have made significant progress in prolonging the lives of women with ovarian cancer, one of our biggest challenges is to improve their quality of life, given the serious side effects of current chemotherapy," noted Larry J. Copeland, MD, Department of Obstetrics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.